Detalles de la búsqueda
1.
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Bioorg Med Chem Lett
; 29(1): 83-88, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30463802
2.
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.
ACS Med Chem Lett
; 15(5): 646-652, 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38746889
3.
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.
J Med Chem
; 66(18): 13205-13246, 2023 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37712656
4.
Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.
J Med Chem
; 65(14): 9819-9845, 2022 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35816678
5.
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
ACS Med Chem Lett
; 12(3): 380-388, 2021 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33738065
6.
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.
ACS Med Chem Lett
; 7(1): 34-9, 2016 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26819662
7.
Inter- and intramolecular annulation strategies to a cyclopentanone building block containing an all-carbon quaternary stereogenic center.
Org Lett
; 17(6): 1401-4, 2015 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25720587
8.
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
J Med Chem
; 56(24): 9934-54, 2013 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24261862
Resultados
1 -
8
de 8
1
Próxima >
>>